0	7	Studies	study	NNS
8	12	into	into	IN
13	16	the	the	DT
17	23	effect	effect	NN
24	26	of	of	IN
27	35	tyrosine	tyrosine	NN
36	47	phosphatase	phosphatase	NN
48	57	inhibitor	inhibitor	NN
58	70	phenylarsine	phenylarsine	NN
71	76	oxide	oxide	NN
77	79	on	on	IN
80	88	NFkappaB	NFkappaB	NNP
89	99	activation	activation	NN
100	102	in	in	IN
103	104	T	t	NN
105	116	lymphocytes	lymphocyte	NNS
117	123	during	during	IN
124	129	aging	aging	NN
129	130	:	:	:
131	139	evidence	evidence	NN
140	143	for	for	IN
144	151	altered	altered	JJ
152	165	IkappaB-alpha	IkappaB-alpha	NNP
166	181	phosphorylation	phosphorylation	NN
182	185	and	and	CC
186	197	degradation	degradation	NN
197	198	.	.	.

200	207	Nuclear	nuclear	JJ
208	214	Factor	factor	NN
215	220	kappa	kappa	NN
221	222	B	B	NNP
223	224	(	(	(
224	232	NFkappaB	NFkappaB	NNP
232	233	)	)	)
234	236	is	be	VBZ
237	238	a	a	DT
239	247	critical	critical	JJ
248	257	regulator	regulator	NN
258	260	of	of	IN
261	268	several	several	JJ
269	274	genes	gene	NNS
275	283	involved	involve	VBN
284	286	in	in	IN
287	293	immune	immune	JJ
294	297	and	and	CC
298	310	inflammatory	inflammatory	JJ
311	320	responses	response	NNS
320	321	.	.	.

322	331	Treatment	Treatment	NNP
332	334	of	of	IN
335	336	T	t	NN
337	342	cells	cell	NNS
343	347	with	with	IN
348	349	a	a	DT
350	357	variety	variety	NN
358	360	of	of	IN
361	368	stimuli	stimulus	NNS
368	369	,	,	,
370	379	including	include	VBG
380	389	TNF-alpha	TNF-alpha	NNP
389	390	,	,	,
391	396	leads	lead	VBZ
397	399	to	to	TO
400	403	the	the	DT
404	417	translocation	translocation	NN
418	420	of	of	IN
421	424	the	the	DT
425	431	active	active	JJ
432	438	p65-50	p65-50	NN
439	450	heterodimer	heterodimer	NN
451	453	to	to	TO
454	457	the	the	DT
458	465	nucleus	nucleus	NN
465	466	,	,	,
467	473	albeit	albeit	IN
474	476	at	at	IN
477	478	a	a	DT
479	484	lower	low	JJR
485	490	level	level	NN
491	493	in	in	IN
494	495	T	t	NN
496	501	cells	cell	NNS
502	506	from	from	IN
507	510	the	the	DT
511	518	elderly	elderly	JJ
518	519	.	.	.

520	522	We	we	PRP
523	534	demonstrate	demonstrate	VBP
535	539	here	here	RB
540	544	that	that	IN
545	557	pretreatment	pretreatment	NN
558	562	with	with	IN
563	566	PAO	PAO	NNP
567	574	results	result	VBZ
575	577	in	in	IN
578	581	the	the	DT
582	592	inhibition	inhibition	NN
593	595	of	of	IN
596	604	NFkappaB	NFkappaB	NNP
605	614	induction	induction	NN
615	617	in	in	IN
618	627	TNF-alpha	TNF-alpha	NNP
628	635	treated	treated	JJ
636	637	T	t	NN
638	643	cells	cell	NNS
643	644	,	,	,
645	655	suggesting	suggest	VBG
656	657	a	a	DT
658	662	role	role	NN
663	666	for	for	IN
667	680	PAO-sensitive	pao-sensitive	JJ
681	692	phosphatase	phosphatase	NN
693	695	in	in	IN
696	699	the	the	DT
700	710	activation	activation	NN
711	713	of	of	IN
714	717	the	the	DT
718	726	NFkappaB	nfkappab	NN
727	730	via	via	IN
731	735	this	this	DT
736	743	pathway	pathway	NN
744	746	in	in	IN
747	752	human	human	JJ
753	754	T	t	NN
755	760	cells	cell	NNS
760	761	.	.	.

762	773	Furthermore	furthermore	RB
773	774	,	,	,
775	777	it	it	PRP
778	790	demonstrates	demonstrate	VBZ
791	795	that	that	IN
796	801	aging	aging	NN
802	806	does	do	VBZ
807	810	not	not	RB
811	820	influence	influence	VB
821	824	the	the	DT
825	836	sensitivity	sensitivity	NN
837	839	of	of	IN
840	844	this	this	DT
845	856	phosphatase	phosphatase	NN
856	857	.	.	.

858	867	Treatment	Treatment	NNP
868	872	with	with	IN
873	876	DMP	DMP	NNP
877	882	prior	prior	JJ
883	885	to	to	TO
886	895	treatment	treatment	NN
896	900	with	with	IN
901	904	PAO	PAO	NNP
905	908	and	and	CC
909	912	TNF	TNF	NNP
913	922	abolishes	abolish	VBZ
923	926	the	the	DT
927	937	inhibition	inhibition	NN
938	945	induced	induce	VBN
946	948	by	by	IN
949	952	PAO	PAO	NNP
952	953	,	,	,
954	956	in	in	IN
957	958	T	t	NN
959	964	cells	cell	NNS
965	969	from	from	IN
970	974	both	both	CC
975	980	young	young	JJ
981	984	and	and	CC
985	988	old	old	JJ
989	995	donors	donor	NNS
995	996	,	,	,
997	1002	alike	alike	RB
1002	1003	.	.	.

1004	1011	Finally	finally	RB
1011	1012	,	,	,
1013	1015	we	we	PRP
1016	1027	demonstrate	demonstrate	VBP
1028	1032	that	that	IN
1033	1034	a	a	DT
1035	1042	failure	failure	NN
1043	1045	to	to	TO
1046	1053	degrade	degrade	VB
1054	1067	IkappaB-alpha	IkappaB-alpha	NNP
1068	1070	in	in	IN
1071	1079	cytosols	cytosol	NNS
1080	1082	of	of	IN
1083	1094	TNF-treated	tnf-treated	JJ
1095	1096	T	t	NN
1097	1102	cells	cell	NNS
1103	1113	pretreated	pretreate	VBN
1114	1118	with	with	IN
1119	1122	PAO	PAO	NNP
1123	1125	is	be	VBZ
1126	1129	due	due	IN
1130	1132	to	to	TO
1133	1136	its	its	PRP$
1137	1149	interference	interference	NN
1150	1154	with	with	IN
1155	1158	the	the	DT
1159	1174	phosphorylation	phosphorylation	NN
1175	1177	of	of	IN
1178	1191	IkappaB-alpha	IkappaB-alpha	NNP
1192	1195	and	and	CC
1196	1199	not	not	RB
1200	1203	due	due	JJ
1204	1206	to	to	TO
1207	1210	its	its	PRP$
1211	1221	inhibitory	inhibitory	JJ
1222	1228	effect	effect	NN
1229	1231	on	on	IN
1232	1243	proteasomal	proteasomal	JJ
1244	1255	degradation	degradation	NN
1255	1256	.	.	.

1257	1262	These	these	DT
1263	1267	data	datum	NNS
1268	1280	collectively	collectively	RB
1281	1288	suggest	suggest	VBP
1289	1293	that	that	IN
1294	1297	PAO	PAO	NNP
1298	1308	interferes	interfere	VBZ
1309	1313	with	with	IN
1314	1317	the	the	DT
1318	1333	phosphorylation	phosphorylation	NN
1334	1337	and	and	CC
1338	1341	the	the	DT
1342	1351	regulated	regulate	VBN
1352	1363	degradation	degradation	NN
1364	1366	of	of	IN
1367	1380	IkappaB-alpha	IkappaB-alpha	NNP
1380	1381	,	,	,
1382	1389	induced	induce	VBN
1390	1392	by	by	IN
1393	1396	TNF	TNF	NNP
1396	1397	,	,	,
1398	1405	without	without	IN
1406	1415	affecting	affect	VBG
1416	1419	the	the	DT
1420	1432	chymotryptic	chymotryptic	JJ
1433	1441	activity	activity	NN
1442	1444	of	of	IN
1445	1448	the	the	DT
1449	1459	proteasome	proteasome	NN
1459	1460	,	,	,
1461	1472	independent	independent	JJ
1473	1475	of	of	IN
1476	1479	age	age	NN
1479	1480	.	.	.